Page last updated: 2024-12-05

phenoperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenoperidine is a potent opioid analgesic that was synthesized in the 1950s. It is structurally similar to fentanyl but has a longer duration of action. Phenoperidine has been studied for its analgesic and sedative effects, and it has been used clinically in the past. However, its use has been limited due to its potential for abuse and its side effects, including respiratory depression and seizures. Research on phenoperidine has focused on understanding its mechanism of action, its potential for abuse, and its therapeutic applications. It has also been studied as a potential treatment for pain in cancer patients and for pain associated with surgery. Phenoperidine's unique pharmacological profile has prompted interest in its potential for therapeutic use. It has been investigated for its ability to provide analgesia with minimal sedation, which could be beneficial in certain clinical settings. Additionally, research has explored its use in combination with other medications to enhance pain relief and reduce side effects.'

Phenoperidine: A narcotic analgesic partly metabolized to meperidine in the liver. It is similar to morphine in action and used for neuroleptanalgesia, usually with droperidol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11226
CHEMBL ID2105385
CHEBI ID135550
SCHEMBL ID80415
MeSH IDM0016522

Synonyms (38)

Synonym
phenoperidinum
fenoperidina
g9bh09j4jw ,
unii-g9bh09j4jw
4-piperidinecarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-, ethyl ester
phenoperidine
562-26-5
D02611
phenoperidine (inn)
phenoperidine [inn:ban:dcf]
fenoperidine
dea no. 9641
r 1406
einecs 209-229-2
1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester
r-1406
fenoperidina [inn-spanish]
phenoperidinum [inn-latin]
CHEBI:135550
ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate
phenoperidin
ids-np-010
CHEMBL2105385
nih 7591
dl-phenoperidine
nih-7591
SCHEMBL80415
ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-piperidinecarboxylate #
IPOPQVVNCFQFRK-UHFFFAOYSA-N
1-(3-hydroxy-3-phenyl-propyl)-4-phenyl-isonipecotic acid ethyl ester
DTXSID90862199
DB13605
Q7181394
phenoperidine [inn]
phenoperidine [mi]
isonipecotic acid, 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-, ethyl ester
phenoperidine [who-dd]
66584-15-4

Research Excerpts

Overview

Phenoperidine is a popular agent for this purpose.

ExcerptReferenceRelevance
"Phenoperidine is a popular agent for this purpose."( Intracranial pressure after phenoperidine.
Goat, VA; Grummitt, RM, 1984
)
1.28

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of propofol given at a constant rate, were studied in 10 children."( [Pediatric anesthesia and pharmacokinetics of propofol administered at a constant rate].
Barale, F; Clément, G; Kantelip, JP; Lassauge, F; Magnin, P; Pequegnot, C; Stimmesse, B; Succi, C; Than, TT, 1990
)
0.28
" The mean distribution half-life (T1/2 alpha) for the five patients was short (2."( Pharmacokinetics of phenoperidine in anaesthetized patients undergoing general surgery.
Fischler, M; Flaisler, B; Levron, JC; Trang, H; Vaxelaire, JF; Vourc'h, G, 1985
)
0.59

Dosage Studied

ExcerptRelevanceReference
" The authors show that the association of neuroleptic drugs has here also an effect of economy of dosage and facilitates the rise in blood pressure."( [Controlled arterial hypotension produced by nitroprusside combined with neuroleptics].
Bauvin, MJ; Campan, L; Clergue, ML, 1976
)
0.26
" An increase in dosage would be necessary in children above 8 years old."( [Pediatric anesthesia and pharmacokinetics of propofol administered at a constant rate].
Barale, F; Clément, G; Kantelip, JP; Lassauge, F; Magnin, P; Pequegnot, C; Stimmesse, B; Succi, C; Than, TT, 1990
)
0.28
" The results suggest that slight or moderate impairment of hepatic function does not significantly affect the kinetics of the drug, and that modification of its dosage may not be required."( Elimination of phenoperidine in liver disease.
Calvey, TN; Chan, K; Isherwood, CN; Murray, GR; Williams, NE, 1984
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (162)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990157 (96.91)18.7374
1990's4 (2.47)18.2507
2000's1 (0.62)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.57 (24.57)
Research Supply Index5.48 (2.92)
Research Growth Index3.94 (4.65)
Search Engine Demand Index168.36 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (64.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (10.60%)5.53%
Reviews11 (5.07%)6.00%
Case Studies10 (4.61%)4.05%
Observational0 (0.00%)0.25%
Other173 (79.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]